IDEAYA Biosciences (IDYA) Net Cash Flow (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Net Cash Flow data on file, last reported at $45.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1.44% year-over-year to $45.0 million; the trailing twelve-month figure through Mar 2026 stood at $28.0 million (up 29.05% YoY), and the FY2025 full-year result was $28.7 million, up 139.48% from the prior year.
• Net Cash Flow grew to $45.0 million in Q1 2026, from -$185.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $217.2 million in Q3 2024 to a low of -$316.0 million in Q4 2024.
• A 5-year average of $3.9 million and a median of $5.2 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 685.64% in 2023 and sank 6173.63% in 2024, its largest moves.
• Tracing IDYA's Net Cash Flow over 5 years: stood at -$33.3 million in 2022, then soared by 115.61% to $5.2 million in 2023, then slumped by 6173.63% to -$316.0 million in 2024, then jumped by 41.18% to -$185.9 million in 2025, then jumped by 124.19% to $45.0 million in 2026.
• Business Quant data shows IDYA's Net Cash Flow at $45.0 million in Q1 2026, -$185.9 million in Q4 2025, and $184.3 million in Q3 2025.